Supplementary Table 1 – Search strategy for Embase

Search performed through Ovid on October 25th, 2018.

# Search strategy for EMBASE via Ovid - Search terms Number of hits

1 rheumatoid arthritis/ 1634052 (rheumatoid arthritis or rheumatoid chronic arthritis or arthritis rheumatoid).ti,ab. 1387993 1 or 2 1846654 ankylosing spondylitis/ 243225 (Spondyloarthritis Ankylopoietica or Ankylosing Spondylarthritis or Ankylosing Spondylarthritides or

Spondylarthritides Ankylosing or Spondylarthritis Ankylosing or Ankylosing Spondylitis or Spondylarthritis Ankylopoietica or Bechterew Disease or Bechterew's Disease or Bechterews Disease or Marie-Struempell Disease or Marie Struempell Disease or Rheumatoid Spondylitis or Spondylitis Rheumatoid or Spondylitis Ankylopoietica or Ankylosing Spondyloarthritis or Ankylosing Spondyloarthritides or Spondyloarthritides Ankylosing or Spondyloarthritis Ankylosing).ti,ab.

20608

6 4 or 5 272857 psoriatic arthritis/ 190088 (Psoriasis Arthritic or Arthritic Psoriasis or Psoriatic Arthritis or Psoriasis Arthropathica or Psoriatic Arthropathy

or Arthropathies Psoriatic or Arthropathy Psoriatic or Psoriatic Arthropathies).ti,ab.14952

9 7 or 8 2060310

rheuma*.ti,ab. 237605

11

ulcerative colitis/ 63758

12

(Idiopathis proctocolitis or Ulcerative Colitis or Colitis Gravis).ti,ab. 52382

13

11 or 12 69427

14

3 or 6 or 9 or 10 or 13 361981

15

(biologic or biologics or tumor necrosis factor blockers or tumor necrosis factor blocker or tumor necrosis factor alpha or tumor necrosis factor alpha inhibitors or tumor necrosis factor alpha inhibitor or Infliximab or Avakine or HSDB 7850 or Remicade or Adalimumab or D2E7 or HSDB 7851 or Humira or Trudexa or Etanercept or Enbrel or HSDB 7849 or Recombinant human TNF or TNFR-Fc or TNR 001 or rhu TNFR:Fc or Golimumab or CNTO 148 or CNTO-148 or CNTO148 or HSDB 7852 or Simponi or Certolizumab or CDP 870 or CDP870 or CZP or Certolizumab pegol or Cimzia or HSDB 7848 or PHA 738144 or PHA-738144 or tocilizumab or Roactemra or rituximab or Mabthera or sarilumab or Kevzara or abatacept or Orencia or baricitinib or Olumiant or tofacitinib or Xeljanz or secukinumab or Cosentyx or ustekinumab or Stelara or ixekizumab or Taltz or apremilast or Otezla or Vedolizumab or tumor necrosis factor or tumor necrosis factor alpha antibody or tumor necrosis factor antagonist or tumor necrosis factor antibody or tumor necrosis factor inhibitor or tumor necrosis factor inhibitors or tumor necrosis factor receptor or tumor necrosis factor-alpha or tumor necrosis factor-alpha antagonist or tumor necrosis ).ti,ab.

287782

16

(persistence or adherence or compliance or retention or discontinuation or time to discontinuation or drug survival or switch or treatment line or cycling or swapping).ti,ab,tw,kw.

800914

17

14 and 15 and 16 5560

18

limit 17 to last 5 years 4139

19

limit 18 to humans 4069

20

limit 19 to ((article or article in press or conference abstract or conference paper) and (conference proceeding or journal) and (adult <18 to 64 years> or aged <65+ years>))

2043

21

limit 20 to (clinical trial or randomized controlled trial or controlled clinical trial or phase 1 clinical trial or phase 2 clinical trial or phase 3 clinical trial or phase 4 clinical trial)

612

22

20 not 21 1431

23

limit 22 to english language 1421

24

remove duplicates from 23 1406

Supplementary Table 2 – Search strategy for Medline

Search performed through Ovid on October 25th, 2018.

# Search strategy for MEDLINE via Ovid - Search terms Number of hits

1 rheumatoid arthritis/ 939142 (rheumatoid arthritis or rheumatoid chronic arthritis or arthritis rheumatoid).ti,ab. 968363 1 or 2 1254104 ankylosing spondylitis/ 138715 (Spondyloarthritis Ankylopoietica or Ankylosing Spondylarthritis or Ankylosing Spondylarthritides or

Spondylarthritides Ankylosing or Spondylarthritis Ankylosing or Ankylosing Spondylitis or Spondylarthritis Ankylopoietica or Bechterew Disease or Bechterew's Disease or Bechterews Disease or Marie-Struempell Disease or Marie Struempell Disease or Rheumatoid Spondylitis or Spondylitis Rheumatoid or Spondylitis Ankylopoietica or Ankylosing Spondyloarthritis or Ankylosing Spondyloarthritides or Spondyloarthritides Ankylosing or Spondyloarthritis Ankylosing).ti,ab.

13477

6 4 or 5 175637 psoriatic arthritis/ 52708 (Psoriasis Arthritic or Arthritic Psoriasis or Psoriatic Arthritis or Psoriasis Arthropathica or Psoriatic Arthropathy

or Arthropathies Psoriatic or Arthropathy Psoriatic or Psoriatic Arthropathies).ti,ab.7799

9 7 or 8 882310

rheuma*.ti,ab. 167006

11

ulcerative colitis/ 32245

12

(Idiopathis proctocolitis or Ulcerative Colitis or Colitis Gravis).ti,ab. 34619

13

10 or 11 43432

14

3 or 6 or 9 or 10 or 13 244314

15

(biologic or biologics or tumor necrosis factor blockers or tumor necrosis factor blocker or tumor necrosis factor alpha or tumor necrosis factor alpha inhibitors or tumor necrosis factor alpha inhibitor or Infliximab or Avakine or HSDB 7850 or Remicade or Adalimumab or D2E7 or HSDB 7851 or Humira or Trudexa or Etanercept or Enbrel or HSDB 7849 or Recombinant human TNF or TNFR-Fc or TNR 001 or rhu TNFR:Fc or Golimumab or CNTO 148 or CNTO-148 or CNTO148 or HSDB 7852 or Simponi or Certolizumab or CDP 870 or CDP870 or CZP or Certolizumab pegol or Cimzia or HSDB 7848 or PHA 738144 or PHA-738144 or tocilizumab or Roactemra or rituximab or Mabthera or sarilumab or Kevzara or abatacept or Orencia or baricitinib or Olumiant or tofacitinib or Xeljanz or secukinumab or Cosentyx or ustekinumab or Stelara or ixekizumab or Taltz or apremilast or Otezla or Vedolizumab or tumor necrosis factor or tumor necrosis factor alpha antibody or tumor necrosis factor antagonist or tumor necrosis factor antibody or tumor necrosis factor inhibitor or tumor necrosis factor inhibitors or tumor necrosis factor receptor or tumor necrosis factor-alpha or tumor necrosis factor-alpha antagonist or tumor necrosis ).ti,ab.

204520

16

(persistence or adherence or compliance or retention or discontinuation or time to discontinuation or drug survival or switch or treatment line or cycling or swapping).ti,ab,tw,kw.

630037

17

14 and 15 and 16 1844

18

limit 17 to last 5 years 1187

19

limit 18 to humans 836

20

limit 19 to "all adult (19 plus years)" 586

21

limit 20 to (adaptive clinical trial or addresses or autobiography or bibliography or biography or case reports or clinical conference or clinical study or clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or comment or comparative study or consensus development conference or consensus development conference, nih or controlled clinical trial or dataset or dictionary or directory or editorial or equivalence trial or "expression of concern" or festschrift or government publications or guideline or interactive tutorial or interview or lectures or legal cases or legislation or letter or meta analysis or news or newspaper article or patient education handout or periodical index or personal narratives or portraits or practice guideline or published erratum or randomized controlled trial or "research support, american recovery and reinvestment act" or research support, nih, extramural or research support, nih, intramural or research support, non us gov't or research support, us gov't, non phs or research support, us gov't, phs or retracted publication or "retraction of publication" or "review" or "scientific integrity review" or

441

systematic reviews or technical report or twin study or video-audio media or webcasts)22

18 not 21 145

23

limit 22 to english language 140

24

remove duplicates from 23 140

Supplementary Table 3 – Search strategies employed for conference databases

Conference Database accessed through

Search term(s) Search date

UEG Week 2018 https://www.ueg.eu/education/library/#stq=*&stp=1&sts=Default&stc=All&stcf=UEG%20Week%202018&stf=All&stms=All&sty=All

“Ulcerative colitis AND switch”; “Rheumatoid arthritis AND switch”; “Ankylosing spondylitis AND switch”; “Psoriatic arthritis AND switch”

December 6, 2018

ECCO 2018 https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2018.html

“Ulcerative colitis AND switch”; “Rheumatoid arthritis AND switch”; “Ankylosing spondylitis AND switch”; “Psoriatic arthritis AND switch”

December 6, 2018

DDW 2018 https://ddw.org/attendee-planning/online-planner

“Ulcerative colitis switch”; “”Rheumatoid arthritis switch”; “Psoriatic arthritis switch”; “Ankylosing spondylitis switch”

December 6, 2018

EULAR 2018 http://scientific.sparx-ip.net/archiveeular/

switch December 6, 2018

ACR 2018 https://acrabstracts.org/ “’Ulcerative colitis’ AND switch”; “’Rheumatoid arthritis’ AND switch”; “’Ankylosing spondylitis’ AND switch”; “’Psoriatic arthritis’ AND switch”

December 7-10, 2018

ISPOR Baltimore 2018 https://tools.ispor.org/RESEARCH_STUDY_DIGEST/research_index.asp

“’auto-immune disorders’ + switch”; “’GI disorders’ + switch”; “’Multiple diseases/no specific disease’ + switch”; “’Rheumatoid arthritis’ + switch”; “’Immune disorder’ + switch”

December 11, 2018

ISPOR EU 2018 https://tools.ispor.org/RESEARCH_STUDY_DIGEST/research_index.asp

“’auto-immune disorders’ + switch”; “’GI disorders’ + switch”; “’Multiple diseases/no specific disease’ + switch”; “’Rheumatoid arthritis’ + switch”; “’Immune disorder’ + switch”

December 11, 2018

Supplementary Table 4 – List of extracted variables

Variable name DefinitionReference details

AuthorsPublication yearType of publicationTitleJournalVolumeIssuePagesAbstract

Study designType of studyData sourceStudy design Retrospective/Prospective/Cross-sectionalCountry /-iesYear(s) of data collectionMaximum follow-up time (months)Censored patients, n (%)

Patient populationDiagnosis, n (%)Total patients, nFemale, n (%)Age, mean (SD)/median (IQR)Mean disease duration, years (SD)

Disease severity DAS28, CDAI, BASDAI/BASFI, PASI, Mayo score, endoscopic disease severity, PGA

Treatment history Bio-naïve patients, yes/noProportion of bio-naïve patients, n (%)

TreatmentsMaximum number of treatments in sequenceTreatment 1 in sequence Name/class of drugTreatment 2 in sequence (if applicable) Name/class of drugNumber of patients switching from Treatment 1 to Treatment 2 (if applicable)Treatment 3 in sequence (if applicable) Name/class of drugNumber of patients switching from Treatment 2 to Treatment 3 (if applicable)

Outcomes

Patient-reported outcomes Including, but not limited to, patient preference and/or satisfaction with switching

Reason for treatment switch Medical/non-medical, as reported by patients and/or healthcare practitioner

Reason for treatment discontinuation Medical/non-medical, as reported by patients and/or healthcare practitioner

Time to treatment switch Mean/median (SD/IQR)

Healthcare setting Hospital (academic/non-academic) vs private practice; Specialized vs non-specialized IBD and rheumatology clinics

Size of unit/center

Supplementary Table 4 – Newcastle-Ottawa Scale for risk of bias assessment

Bias domain Item Reviewer’s judgment StarsCohort studies

Selection

Representativeness of the exposed cohort

Truly representative of the average __________ (describe) in the community 1Somewhat representative of the average __________ (describe) in the community 1Selected group of users, e.g. nurses, volunteers 0No description of the derivation of the cohort 0

Selection of the non-exposed cohort*

Drawn from the same community as the exposed cohort 1*Drawn from a different source 0*No description of the derivation of the non-exposed cohort 0*

Ascertainment of exposure

Secure record (e.g. surgical records) 1Structured interview 1Written self report 0No description 0

Demonstration that outcome of interest was not present at start of study*

Yes 1*

No 0*

Comparability Comparability of cohorts on the basis of the design or analysis

Study controls for age, gender, or indication 1Study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor) 1

Outcome

Assessment of outcome

Independent blind assessment 1Record linkage 1Self report 0No description 0

Was follow-up long enough for outcomes to occur?*

Yes (select and adequate follow up period for outcome of interest) 1*No 0*

Adequacy of follow up of cohorts

Complete follow up – all subjects accounted for 1Subjects lost to follow up unlikely to introduce bias – small number lost - > __% (select an adequate % follow up, or description provided of those lost) 1

Follow up rate <____% (select an adequate %) and no description of those lost 0No statement 0

*Item not assessed; no applicable score

Supplementary Table 6 – Characteristics of studies included in the review

Author(s), year

Type Study design

Country /-ies

Year(s) of data collection

Maximum follow-up time, months

Diagnosis, n (%)

Total number of patients

Female, n (%) Age (Mean (SD)/Median (IQR))

Proportion of treatment-naïve patients, n (%)

Number of treatment lines

Al Tabaa, 2018 1

Conference abstract

Prospective France 2016-2017 6 Switchers to bETN: RA 51.1%, SpA 48.9%Non-switchers: RA 44.9%, SpA 55.1%

183 Switchers to bETN: 57.4%Non-switchers: 51.6%

Switchers to bETN: 52.1 (15)Non-switchers: 50.5 (15)

NR 2

Alkoky, 2018 2

Conference abstract

Prospective UK 2017 6 RA: 87PsA: 30AS: 41

158 RA: 70 (80.5%)PsA: 12 (29.3%)AS: 7 (23.3%)

RA: 61.68 (13.61)PsA: 54.77 (13.54)AS: 41.9 (9.8)

NR 3

Attipoe, 2018 3

Conference abstract

Retrospective UK 2017 NA RA: 68%PsA: 16%AS: 11%

107 64% 18-49 years: 20%50+: 80%

NR 2

Baganz, 2018 4

Conference abstract

Prospective Germany 2015-April 2018

6 RA: 579 (100%)

579 NR SB4: 58 yearsoETN: 59 years mean or median not specified

NR 1

Bolge, 2015 5 Article Retrospective USA 2011 NA RA: 250 (100%)

250 182 (72.8%) 51 NR 1

Bressler, 2018 6

Conference abstract

Retrospective UK 2015-2016 25.5 UC: 34 (68%) 34 32% 44.4 (15.5) 34 (100%) 1

Choquette, 2018 7

Conference abstract

Retrospective Canada 2006-2017 NR RA: 641 (100%)

641 77.50% 47.1 (13.4) 641 (100%) 1

Choquette, 2018 8

Conference abstract

Retrospective Canada 2006-2017 NR RA: 247 (100%)

247 74.90% 45.2 (12.9) 0 (0%) 2

Conesa Mateos 2018 9

Conference abstract

NR Spain NR 12 PsA: 262 (100%)

262 56.50% 49.9 (11.9) No prior bDMARD: 28.4%;1 prior bDMARD: 38.1%; 2 or more prior bDMARDs: 33.5%

1

Curtis 2018 10 Conference abstract

Prospective France, Germany, Italy, Spain, UK

2017 NA RA: 359 (100%)

359 75.80% 56.5 (12.7) 0 (0%) 2

De Cock, 2017 11

Conference abstract

Retrospective UK 2015-2016 6 RA: 414 (100%)

414 Bio-naïve: 108 (78%)Switched from ref prod: 181 (75%)Not switched from ref prod: 28 (82%)

Bio-naïve: 56 (48-64.5)Switched from ref prod: 67 (57-72)Not switched from ref prod: 59.5 (44.5-68)

138 (33%) 2

De Cock, 2018 12

Conference abstract

Retrospective UK 2015-2017 6 RA: 691 (100%)

691 512 (74.1%) Benepali: 64.5 (55-71)Inflectra: 70 (65-73)Remsima: 66 (58-72)

0 (0%) 3

De Keyser, 2014 13

Article Prospective Belgium 2006-2011 Mean weeks (SD): 93.1 (2.6)

RA: 649 (100%)

649 57.4 (0.5) NR (0.9%?) 1

Dyball, 2017 14

Conference abstract

Retrospective UK NR NR RA: 38 (100%) 38 69% 59.3 (NR) 0 (0%) 3

Exposito-Molinero, 2018 15

Conference abstract

NR Spain NR 12 AxSpa: 336 (100%)

336 43.50% 45.8 (12.1) 27.20% 1

Favalli, 2016 16

Conference abstract

Retrospective Italy 2005-2015 96 AxSpA: 316PsA: 298

614 AxSpA: 30.1%PsA: 48.3%

AxSpA: 42.8 (12.1)PsA: 47.8 (12.1)

614 (100%) 1

Forejtova, 2017 17

Conference abstract

NR Czech republic

NR 6 AS: 36 (100%) 38 6 (15.8%) 27 (8) 34 (89.5%) bio-naïve when initiating INF therapy

2

Glintborg, 2017 18

Conference abstract

Prospective Denmark 2016-2017 12 RA: 937PsA: 351AxSpA: 335

1623 RA: 692 (74%)PsA: 160 (46%)AxSpA: 113 (34%)

RA:60 (48-69)PsA: 52 (43-61)AxSpA: 48 (39-57)

0 (0%) 2

Glintborg, 2017 19

Article Prospective Denmark 2000-2015 413 days RA: 403PsA: 120AxSpA: 279

802 51% Median (IQR): 55 (44-66)

NR 2

Glintborg, 2018 20

Conference abstract

Prospective Denmark 2016-2017 12 RA: 80PsA: 20AxSpA: 20

120 RA: 73%PsA: 55%AxSpA: 35%

RA: 59 (52-70)PsA: 45 (36-56)AxSpA: 43 (38-56)

0 (0%) 3

Gonzalez Fernandez, 2018 21

Conference abstract

Retrospective Spain 2013-2015 36 AxSpA: 131PsA: 79

210 40% 49 (12) 0 (0%) 2

Gonzalez Munoza, 2018 22

Conference abstract

Retrospective Spain NR 26 CD: 58UC: 49

107 NR NR NR 1

Hacioglu, 2017 23

Conference abstract

Retrospective Turkey 2012-2016 48 RA: 104 (100%)

104 79 (76%) 47.7 (13) 104 (100%) 1

Haugeberg, 2018 24

Conference abstract

Retrospective Norway 2016-2018 Mean obs time for pts still on SB4: 1.23 y

RA: 191 (100%)

191 67% 60.8 0 (0%) 2

Hendricks, 2017 25

Conference abstract

Prospective Denmark 2016-2017 8 IMRD 85 NR NR NR 3

Holroyd, 2017 26

Conference abstract

Retrospective UK NR 6 RA: 58AS: 15PsA: 16Enteropathic arthritis: 4

92 56 (60.9%) 55.9 (14.9) NR 3

Hoque, 2018 27

Conference abstract

Retrospective UK 2016-2017 12 RA: 43SpA: 43PsA: 27

94 47 (50%) 53.4 NR 3

Kadar, 2014 28

Article Retrospective Hungary NR Average:; 20 months

RA: 126AS: 38PsA: 11

175 NR RA: 60 (21-84)AS: 46 (20-67)PsA: 57 (24-74)

NR 1

Karakoc, 2018 29

Conference abstract

Retrospective Turkey 2014-2017 30 RA: 192 (100%)

192 163 (85%) Median age: 56 (21-81)

92 (48%) 1

Kellner, 2017 30

Conference abstract

Prospective Germany 2015-2016 NA Chronic inflammatory rheumatic disease

41 NR NR 9 (21.95%) 2

Layegh, 2018 31

Conference abstract

Prospective The Netherlands

2015-2018 24 RA: 41PsA: 4

45 32 (71) 65 (14) NR 3

Lee, 2018 32 Conference abstract

Retrospective UK 2016-2017 8 RA/AS/PsA 56 37 (66.1%) Pts persistent with SB4: 57.2Pts switched to 3rd biologic: 55.4Pts switched back to ETN: 39.5

NR 3

Leon, 2016 33 Article Retrospective Spain 31 December 1999 - 15 December 2013

1869 patient years

RA: 451 (100%)851 courses of BA (1869 patient years) (100%)

451 366 (81.33) Age at diagnosis Mean(SD): 52.38 (13.67)

58% of treatment courses

1

Lorenzin, 2015 34

Article Retrospective Spain 2003- 5 years AS: 70 (100%) 70 Responders: 6 (17.1%)Non-responders: 12 (65.7%)

Responders: 50.3 (12.5)Non-responders: 48.5 (11.0)

NR 1

Ma, 2018 35 Conference Prospective UK NR 12 RA: 32 (64%) 50 equal gender Mean: 60 years NA 2

abstract AS: 15 (30%)PsA: 3 (6%)

distribution (29-83)

Madenidou, 2018 36

Conference abstract

Retrospective UK 2016-2018 12 RA : 36 AxSpA: 23PsA: 13

72 RA : 27 (75%) AxSpA: 7 (30%)PsA: 6 (46%)

RA: 62 (56-77)AxSpA: 56 (46-66)PsA: 54 (51.5-67.5)

NR 3

Mease, 2017 37

Conference abstract

Retrospective USA April 2013-January 2015

Mean (SD) follow-up: 17.8 (7.1) months

AS: 155 (100%)

155 NR NR NR 1

Mease, 2018 38

Conference abstract

Retrospective USA March 2013-January 2017

579.2 person-years

PsA: 318 (100%)

318 NR NR 171 (53.8%) 2

Movahedi, 2018 39

Conference abstract

Prospective Canada NR Mean (SD) follow-up: 2.4 (2.0) years

RA: 796 (100%)

796 79.80% mean (SD): 56.2 (12.8)

NR 1

Muskens, 2018 40

Conference abstract

Prospective Netherlands 01-06-2016 to 23-10-2017

Median (IQR) days: 307 (196-357)

RA, SpA, PsA: not differentiated; n=69

ETN: 86Switchers: 69 (80% of ETN originator users that switched to biosimilar)

NR NR NR 3

Narula, 2018 41

Article Retrospective USA May 2014-December 2016

median 10 (IQR 5.5-14)

UC: 321 (100%)

321 158 (49%) 38 (27-55) TNF naïve 93 (29%)

1

Neovius, 2015 42

Article Retrospective Sweden 2003-2011 5 years RA: 9139 (100%)

9139 76% mea: 56 9139 (100% 1

Nolkha, 2018 43

Conference abstract

Prospective UK November 2010-December 2017

NR RA: 220 (100%)

220 176 (80%) Mean (SD): 67.83 (10.32)

13 (6%) 2

Oldroyd, 2018 44

Article Retrospective UK February 2008-December 2011

48 RA: 1629 (100%)

1629 1243 (76%) 60.8 (51.8-67.9) 258 (16%) 2

Orlandini, 2017 45

Conference abstract

Prospective Italy March 2015 - November 2016

NR UC: 27 (100%) 27 Bio-naïve: 4 (36%)Bio-experienced: 10 (62%)

NR 11 (41%) 1

Patel, 2018 46 Conference abstract

Prospective UK February 2016-NR

NR RA: 168 (100%)

168 NR NR NA 3

Perez Conference Prospective Spain NR 12 PsA: 66 66 34 (51.5%) 47.2+/-11.3 NR 1

Albaladejo, 2018 47

abstract (100%)

Ramos, 2018 48

Conference abstract

Retrospective Spain (Canary Islands)

2009-2015 12 UC: 79 (100%) 79 35 (44.3%) 44 +/- 15 NR 2

Rashid, 2016 49

Article Retrospective USA 2007-2012 12 RA: 2171 2171 1762 (81.2%) 50 (12.60 2171 (100%)

2

Rolon Campuzano, 2018 50

Conference abstract

Prospective Spain Jan 2006 - December 2017

NR RA: 347 (100%)

347 89.60% median: 57.8(IQR: 48-65)

347 (100% 2

Rusman, 2018 51

Article Retrospective Netherlands 2004-2014 10 years AS: 122(100%)

122 48 (39.3)% 43.5 (17-75) NR 3

Salmon, 2018 52

Conference abstract

Retrospective France January 2008-July 2016

12 RA: 517 (100%

517 74% 61.4+/-13.3 22% 1

Sari, 2017 53 Conference abstract

Retrospective Turkey Up to August 2016

40 RA: 158 (100%)

158 82% 53.6+/-11.3 NR 1

Scherlinger, 2018 54

Article Prospective France 2015-2016 Median: 33 weeks (6-50)

RA: 14AS: 63PsA: 12

89 38 (43%) 50.5 (13.3) NR 3

Scherlinger, 2018 55

Article Prospective France 2017 NA RA: 20 (38%)SpA: 32 (62%) (AS - 24, PsA - 4, SAPHO - 4, Reactive arthritis - 2)

52 29 (56%) 51.7 (14.4) Enbrel was 1st line in 77% (n=40)

3

Schmitz, 2017 56

Article Prospective Netherlands NR 15 Rheumatoid arthritis (RA) 14 (52%)Psoriatic arthritis (PsA) 5 (19%)Ankylosing spondylitis (AS) 4 (15%)Spondylo arthritis (SpA) 1 (3.7%)Psoriasis (PsO) 1 (3.7%)Polyarthritis with ulcerative colitis 1 (3.7%)Periferal arthritis with ulcerative colitis 1 (3.7%)

27 17 (63) 60 (48-8) NR 2

Sebastiani, 2018 57

Conference abstract

Retrospective Italy NR 12 RA: 477 (100%)

477 382 (80.1%) 51.3 +/-14.1 NR 1

Sepriano, 2016 58

Article Prospective Portugal 2001-2014 13 years SpA: 954 (100%)

954 With discontinuation: 45.3%without discontinuation: 38.2%

with discontinuation: 41 (11.7)without discontinuationL 41.9 (12.2)

100% 1

Shah, 2018 59 Conference abstract

Prospective UK January 2017-June 2017

6 RA: 151 (100%)

151 NR NR NR 3

Thomas, 2018 60

Article Retrospective Greece Sep 2010-June 2014

4 years RA: 166PsA: 82AS: 80

328 RA: 89.2%PsA: 67%AS:51%

RA: 58.3 (13.3)PsA: 52.1 (11.9)AS: 45.7 (11.3)

Treatment Previous bDMARDs use, n (%) TotalRA: 91 (55) PsA: 49 (60)

AS: 56 (70)1 previous bDMARDRA: 38 (23) PsA: 18 (22)

AS: 14 (17.5)2 previou bDMARDSRA: 21 (13) PsA: 22 (27)

AS: 20 (25)≥3 previous bDMARDSRA: 32 (19) PsA: 9 (11) AS: 22 (27.5)

1

Tropé, 2018 61 Conference abstract

Cross-sectional

France NR NA RA: 504 (100%)

504 82% Mean 62.4 40% 2

Tweehuysen, 2018 62

Article Prospective Netherlands June 2016-May 2017

NR switch cohort: 625historic: 600

Switch Cohort625 TotalRA: 433PsA: 128AS: 64

341 (55%) 57 (14 NR 2

Tweehuysen, Article Prospective Netherlands July 2015 - 6 months RA: 75 192 RA: 53 (71) RA: 63 +/- 13 Number of 2

2018 63 PsA: 50AS: 67

PsA: 27 (54)AS: 19 (28)

PsA: 53 +/-11AS: 48 +/- 11

previous biologic drugs, median (IQR)RA: 0PsA: 0 (0-2)AS:0 (0-1)

Uslu, 2018 64 Conference abstract

Retrospective Turkey June 2013-January 2017

NR CT-P13RA: 17 (15.32%)AS+NraxSpa: 80 (70.2%)PsA: 7 (6.31%)Other: 7 (6.31%)INFRA: 54 (10.74%)AS+NraxSpa: 334 (66.4%)PsA: 39 (7.75%)Other: 76 (15.11%)

614CT-P13: 111INF: 503

CT-P13Total: 74 (65.49)RA: 14 (82%)AS+NraxSpa: 50 (63%)PsA: 4 (57%)other: 4 (57%)INFTotal: 241 (47.25%)RA: 44 (81%)AS+NraxSpa: 140 (42%)PsA: 25 (64%)Other: 29 (38%)

NR CT-P13: 76.6%INF: 67.4%

1

Valido, 2018 65

Conference abstract

Prospective Spain 2016 12 (median: 261 days)

SpA: 36 (60%)RA: 16 (27%)PsA: 8 (13%)

60 Total: 21 (35%)SpA: 6 (17%)RA: 14 (87%)PsA: 1 (12%)

MedianTotal: 23 (48-64)SpA: 50 (41-59)RA: 59 (52-70)PsA: 56 (48-64)

Total: 4 (6.7%)SpA: 1 (2.8%)RA: 3 (18.8)PsA: 0 (0%)

2

Varela, 2016 66

Article Prospective Spain November 2000- March 2014

NR 531 TotalRA: 282 (53.1)SpA: 249 (46.9)By drug242 (45. 6%) patients receiving IFX, 159 (29.8%) receiving ETN and 131(24.7%) receiving ADA

531 NR NR NR 1

Vieira-Sousa, 2018 67

Conference abstract

NR Portugal NR 200 PsA: 750 (100%)

750 377 (50.3%) 47.6 (11.6) 0 (0%) 3

Viola, 2018 68 Conference abstract

Retrospective Italy NR 12 UC (100%) 76 29 (38%) 46 (16) 0 (0%) 2

Xibille, 2018 69

Conference abstract

Retrospective Mexico April 2016-January 2018

NR RA: 69.9%AS: 12.5%PsA: 5.5%

216 89.10% 49 (15.2 NR 2

Zengin, 2018 70

Conference abstract

Retrospective Turkey NR 60 weeks RA: 118 (100%)

118 NR NR 43 (36.4%) 1

References

1. Al Tabaa O, Etcheto A, Miceli-Richard C, Anna M, Dougados M. Switch from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: the experience of Cochin University Hospital Paris-France. Paper presented at: Annual European Congress of Rheumatology, EULAR2018.

2. Alkoky H, Pakozdi A, Tahir H. Benepali switches in clinical practice - a positive single centre experience. Arthritis and Rheumatology. 2018;70 (Supplement 9):2788-2789.

3. Attipoe L, Patel S, Birt R, Crooks J, Hunt K, Grigoriou A. What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a south west london general hospital? Rheumatology (United Kingdom). 2018;57 (Supplement 3):iii63.

4. Baganz L, Meissner Y, Herzer P, et al. Treatment continuation on the etanercept original in comparison with a biosimilar. Arthritis and Rheumatology. 2018;70 (Supplement 9):2789-2790.

5. Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence. 2015;9:121-131.

6. Bressler B, Greenup AJ, Bassel M, et al. Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn's disease patients (EVOLVE) in Canada: Interim results. Journal of Crohn's and Colitis. 2018;12 (Supplement 1):S382.

7. Choquette D, Bessette L, Alemao E, et al. Retention rates of TNF inhibitors and abatacept used as a first biologic dmard in the treatment of rheumatoid arthritis: 8 years of experience from the Rhumadata registry. Journal of Rheumatology. 2018;45 (7):1053.

8. Choquette D, Bessette L, Haraoui B, et al. Rituximab shows better sustainability than TNF inhibitors when used following initial biologic DMARD failure in the treatment of rheumatoid arthritis: 8 years of real-world observations from the RHUMADATA clinical database and registry. Annals of the Rheumatic Diseases. 2017;76 (Supplement 2):845-846.

9. Conesa Mateos A, Fernandez-Prada M, Exposito-Molinero R, et al. Certolizumab Pegol's effectiveness, retention rate and safety in psoriatic arthritis. Routine clinical practice data. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1579.

10. Curtis JR, Sullivan E, Kershaw J, Blackburn S, Mahajan P, Boklage S. Physician-reported behaviours and treatment trends of tumour necrosis factor inhibitor use: Cycling versus switching in five European countries: France, Germany, Italy, Spain and the UK. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1385-1386.

11. De Cock D, Watson K, Hyrich KL. Biosimilars in the UK: Early real world data from the british society for rheumatology biologics registers for rheumatoid arthritis. Annals of the Rheumatic Diseases. 2017;76 (Supplement 2):555-556.

12. De Cock D, Dyball S, Kearsley-Fleet L, Watson K, Hyrich K. Profiling rheumatoid arthritis biosimilar switchers: Data from the British society for rheumatology biologics register for rheumatoid arthritis. Paper presented at: Annual Conference of the British Society for Rheumatology2018.

13. De Keyser F, Hoffman I, Durez P, et al. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis registry. Journal of Rheumatology. 2014;41(9):1761-1765.

14. Dyball S, Hoskins V, Christy-Kilner S, Haque S. Effectiveness and tolerability of benepali in rheumatoid arthritis patients switched from enbrel. Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP. 2017;69(Supplement 10).

15. Exposito-Molinero R, Garcia-Portales R, Lamua-Riazuelo JR, et al. Efectiveness and retention rate of certolizumab pegol in spondyloarthritis. Real life data. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1550.

16. Favalli EG, Selmi C, Becciolini A, et al. The 8-year retention rate of the first TNF-inhibitor in the treatment of spondyloarthropathies: Real-life data from a multicentric local registries. Annals of the Rheumatic Diseases. 2016;75 (Supplement 2):810.

17. Forejtova S, Zavada J, Szczukova L, Jarosova K, Philipp T, Pavelka K. A non-medical switch from originator infliximab to biosimilar CT-p13 in 36 patients with ankylosing spondylitis: 6-months clinical outcomes from the Czech Biologic registry attra. Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP. 2017;69(Supplement 10).

18. Glintborg B, Omerovic E, Danebod K, et al. One-year clinical outcomes in 1623 patients with inflammatory arthritis who switched from originator to biosimilar etanercept-an observational study from the danish danbio registry. Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP. 2017;69(Supplement 10).

19. Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Annals of the Rheumatic Diseases. 2017;76(8):1426-1431.

20. Glintborg B, Sorensen IJ, Omerovic E, et al. One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. An observational danbio study. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):595-596.

21. Gonzalez Fernandez CM, Alegre-Sancho JJ, Garcia-Carazo S, et al. Persistence on golimumab as second line biological therapy in patients with spondyloarthritis (axial spondyloarthritis and psoriatic arthritis). Go-beyond, a retrospective study. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1543.

22. Gonzalez Munoza C, Mesonero F, Bargallo A, et al. Efficacy and safety of vedolizumab in inflammatory bowel disease: Real-life experience. Journal of Crohn's and Colitis. 2018;12 (Supplement 1):S486.

23. Hacioglu A, Hatemi G, Esatoglu SN, et al. Tapering TNF inhibitors in rheumatoid arthritis: A retrospective study. Annals of the Rheumatic Diseases. 2017;76 (Supplement 2):1186.

24. Haugeberg G, Bakland G, Rodevand E, Fevang BT, Diamantopoulos A, Hansen IJW. Drug survival and reason for drop-out in rheumatoid arthritis patients with a nonmedical switch from originator to biosimilar etanercept-preliminary data from a Norwegian multicenter study. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1383.

25. Hendricks O, Horslev-Petersen K. When etanercept switch fails-clinical considerations. Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP. 2017;69(Supplement 10).

26. Holroyd C, Wallis D, Bennett S, Clayton P, Edwards CJ. Switching from bio-original etanercept to biosimilar etanercept SB4: Patient acceptability and outcomes in the real world. Annals of the Rheumatic Diseases. 2017;76 (Supplement 2):1180.

27. Hoque T, Suddle A, Herdman L, Kitchen J. Patient perceptions of switching to biosimilars. Rheumatology (United Kingdom). 2018;57 (Supplement 3):iii67-iii68.

28. Kadar G, Balazs E, Soos B, et al. Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases. Clinical Rheumatology. 2014;33(3):329-333.

29. Karakoc Y, Ercan I. Drug survival analysis of tofacitinib in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1411.

30. Kellner H. High acceptance rate in RA, as and PSA patients when being started on biosimilar TNF or being switched from the original TNF MAB (remicade, enbrel)-a

single center experience. Annals of the Rheumatic Diseases. 2017;76 (Supplement 2):1436.

31. Layegh Z, Ruwaard J, Hebing RC, et al. Efficacious transition from reference product infliximab to the biosimilar in daily practice. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1733.

32. Lee SY, Szeto MCH, Galloway JB. Bio-similar to bio-originator switchback: Not a reliable quality indicator. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1727-1728.

33. Leon L, Rodriguez-Rodriguez L, Rosales Z, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scandinavian journal of rheumatology. 2016;45(6):456-460.

34. Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskeletal Disorders. 2015;16 (1) (no pagination)(166).

35. Ma J, Petford S, Jones L, Douglas K, John H. Audit of the clinical efficacy and safety of etanercept biosimilar to its product in patients with inflammatory arthritis: Experience from a district general hospital in The United Kingdom. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1386.

36. Madenidou A-V, Jeffries A, Varughese S, et al. Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study. Paper presented at: American College of Rheumatology, ACR2018.

37. Mease PJ, Van Der Heijde D, Karki C, Liu M, Park Y, Greenberg JD. Discontinuation of tumor necrosis factor inhibitor therapy in us patients with ankylosing spondylitis: Data from the corrona psoriatic arthritis/spondyloarthritis (PSA/SPA) registry. Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP. 2017;69(Supplement 10).

38. Mease P, Liu M, Gershenson B, Hur P, Greenberg J. Discontinuation and switching patterns of tumour necrosis factor inhibitor (TNFi) therapy in TNFi-naive and TNFi-experienced patients with psoriatic arthritis in the us corrona psoriatic arthritis/ spondyloarthritis (PSA/SPA) registry. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):382.

39. Movahedi M, Hepworth E, Mirza R, Cesta A, Larche M, Bombardier C. Time to discontinuation of biologic therapy by mechanism of action in rheumatoid arthritis: Results from a rheumatoid arthritis cohort. Arthritis and Rheumatology. 2018;70 (Supplement 9):624-625.

40. Muskens WD, Rongen-van Dartel SAA, Adang E, Van Riel PL. The influence of switching from etanercept originator to its biosimilar on effectiveness and and the impact of shared decision making on retention and withdrawal rates. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1399.

41. Narula N, Peerani F, Meserve J, et al. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology. 2018;113(9):1345-1354.

42. Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Annals of the Rheumatic Diseases. 2015;74(2):354-360.

43. Nolkha N, Sheeran T, Venkatachalam S. Drug survival and efficacy of abatacept in rheumatoid arthritis patients in routine care-7 year experience from a single centre in the United Kingdom. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):959-960.

44. Oldroyd AGS, Symmons DPM, Sergeant JC, et al. Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018;57(6):1089-1096.

45. Orlandini B, Dragoni G, Bagnoli S, Deiana S, MacRi G, Rogai F. Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naive patients with moderate to severe ulcerative colitis: Experience from a tertiary referral centre. Journal of Crohn's and Colitis. 2017;11 (Supplement 1):S284.

46. Patel D, Ahmed TJ, Levy S, Rajak R, Sathananthan R, Horwood N. Analysis of rheumatoid arthritis patients who failed the switch from originator etanercept to biosimilar etanercept in Croydon. Rheumatology (United Kingdom). 2018;57 (Supplement 3):iii199.

47. Perez Albaladejo L, Notario Ferreira I, Anon Onate I, et al. Survival at 6 and 12 months of ustekinumab in patients with psoriatic arthritis in conditions of clinical practice. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1591-1592.

48. Ramos L, Hernandez Camba A, De La Barreda R, et al. Clinical outcome with biological therapy in ulcerative colitis: Real-world clinical setting from a multi-centre observational study. Journal of Crohn's and Colitis. 2018;12 (Supplement 1):S504.

49. Rashid N, Lin AT, Aranda G, et al. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. Journal of Medical Economics. 2016;19(6):568-575.

50. Rolon Campuzano R, Coronel Ale AL, Cerda OL, et al. Patterns of change OFA second biological DMARD in a cohort of rheumatoid arthritis patients. Journal of Clinical Rheumatology. 2018;24 (3 Supplement 1):S4.

51. Rusman T, Ten Wolde S, Euser SM, van der Ploeg T, van Hall O, van der Horst-Bruinsma IE. Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: A retrospective cohort study in daily practice. International Journal of Rheumatic Diseases. 2018;21(4):836-842.

52. Salmon JH, Letarouilly JG, Coquerelle P, et al. Therapeutic maintenance of abatacept in rheumatoid arthritis: Results of the RIC-ABA study (517 patients). Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1385.

53. Sari A, Armagan B, Kilic L, et al. Abatacept experience in biologic naive rheumatoid arthritis patients: HUR-BIO real life results. Annals of the Rheumatic Diseases. 2017;76 (Supplement 2):854-855.

54. Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. Joint Bone Spine. 2018;85(5):561-567.

55. Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Seminars in Arthritis and Rheumatism. 2019;48(5):927-932.

56. Schmitz EMH, Benoy-De Keuster S, Meier AJL, et al. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clinical Rheumatology. 2017;36(9):2129-2134.

57. Sebastiani M, Manfredi A, Iannone F, et al. Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the Italian Gisea registry. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):957.

58. Sepriano A, Ramiro S, van der Heijde D, et al. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study. Arthritis and Rheumatology. 2016;68(11):2671-2679.

59. Shah K, Flora K, Penn H. Clinical outcomes of a multi-disciplinary switching programme to biosimilar etanercept for patients with rheumatoid arthritis. Rheumatology (United Kingdom). 2018;57 (Supplement 3):iii143-iii144.

60. Thomas K, Flouri I, Repa A, et al. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: Real world data from 328 patients. Clinical and Experimental Rheumatology. 2018;36(2):254-262.

61. Trope S, Thibaud G, Alliot F, Formont D, Krouri S. Quality of life of rheumatoid arthritis patients treated with biologics. Arthritis and Rheumatology. 2018;70 (Supplement 9):1723.

62. Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study. Arthritis and Rheumatology. 2018;70(9):1408-1418.

63. Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis and Rheumatology. 2018;70(1):60-68.

64. Uslu S, Can G, Senel S, et al. The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry. Paper presented at: American College of Rheumatology, ACR2018.

65. Valido A, Silva-Dinis J, Saavedra MJ, Bernardo N, Fonseca JE. Efficacy and cost analysis of a systematic switch from originator infliximab to biossimilar CT-P13 of all patients with inflammatory arthritis from a single centre. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1712-1713.

66. Varela H, Villamanan E, Plasencia C, et al. Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: Therapy discontinuations related to side effects. Journal of Clinical Pharmacy and Therapeutics. 2016;41(3):306-309.

67. Vieira-Sousa E, Eusébio M, Ávila-Ribeiro P, et al. Tumour necrosis factor inhibitors persistence in psoriatic arthritis patients. Paper presented at: Annual European Congress of Rheumatology, EULAR2018.

68. Viola A, Pugliese D, Renna S, et al. Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study. Paper presented at: Conference of European Crohn´s and Colitis Organisation2018.

69. Xibille D, Carrillo S, Sicsik S, et al. Ps in the use of biologic drugs and adverse events in patients with rheumatic disease from a national biologics registry in Mexico. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1377.

70. Zengin B, Inanc N, Akar S, et al. Similar efficacy of tofacitinib on disease activity in rheumatoid arthritis patients with and without previous biologicals; results from the turkbio registry. Annals of the Rheumatic Diseases. 2018;77 (Supplement 2):1401-1402.